1)Cooperberg MR, Cowan J, Broering JM, et al:High-risk prostate cancer in the United States. World J Urol 26:211-218, 2008
2)D'Amico AV, Whittington R, Malkwicz SV, et al:Biochemical outcome after radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
3)日本泌尿器科学会:前立腺癌診療ガイドライン.金原出版,東京,p197,2006
4)Akaza H:Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology 85:110-120, 2010
5)Ueno S, Namiki M, Fukagai T, et al:Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer:a retrospective multicenter study. Int J Urol 13:1494-1500, 2006
6)日本泌尿器科学会:前立腺癌診療ガイドライン.金原出版,東京,p132,2006
7)中田誠司,中野勝也,高橋溥朋,他:内分泌療法後のPSA再燃をきたした前立腺癌の予後因子.日泌尿会誌 7:685-690,2005
8)Petrylak DP, Tangen CM, Hussain MH, et al:Docetaxel and estramustine compared mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
9)Akaza H, Homma Y, Usami M, et al:Efficacy of primary hormone therapy for localized or locally advanced prostate cancer:results of a 10-year follow-up. BJU Int 98:573-579, 2006